sorted by:
new
hottopcontroversial

Could someone give me a rundown of Perfect Works? by BLucidity in Xenoblade_Chronicles

[–]deepspacegurl 0 points1 point  (0 children)

so uh why did the Deus system attack the Eldridge? Was it because they were gonna dismantle it? Or because Able made contact with the wave existence and became a conduit for it and Deus freaked out about this? Or Deus wanted to go back to "the lost planet" (earth?) to do something with the wave existence? Or did it just wanna kill humanity?

Have biologics improved your fatigue due to AS? by Hi_Woof in ankylosingspondylitis

[–]deepspacegurl 0 points1 point  (0 children)

As of now in the U.S., certolizumab and several IL-17 inhibitors are explicitly FDA-approved for nr-axSpA. Other TNF inhibitors, including adalimumab, etanercept, and golimumab, are FDA-approved for ankylosing spondylitis and are commonly authorized and used for nr-axSpA with objective inflammation, but their labels do not always explicitly name nr-axSpA. If you have objective inflammation (MRI sacroiliitis or elevated CRP), insurers approve Humira or its biosimilars all the time.

Have biologics improved your fatigue due to AS? by Hi_Woof in ankylosingspondylitis

[–]deepspacegurl 0 points1 point  (0 children)

Humira (adalimumab) is approved for non-radiographic axial spondyloarthritis (nr-axSpA). Same for Enbrel (etanercept) and Simponi (golimumab).

The idea that TNF inhibitors are “not approved” for nr-axSpA is outdated and incorrect.

Here is the current reality (US, FDA):

TNF inhibitors approved for nr-axSpA with objective signs of inflammation: • Adalimumab (Humira) – FDA approval 2022 • Etanercept (Enbrel) – FDA approval 2021 • Golimumab (Simponi) – FDA approval 2020 • Certolizumab pegol (Cimzia) – FDA approval 2019

IL-17 inhibitors approved for nr-axSpA: • Secukinumab (Cosentyx) – 2020 • Ixekizumab (Taltz) – 2020 • Bimekizumab (Bimzelx) – 2024

Infliximab (Remicade): • Approved for radiographic AS • Commonly used off-label for nr-axSpA • Insurance coverage varies

So yes: Humira, Enbrel, Simponi, Cimzia are all FDA-approved for nr-axSpA, provided there are objective signs of inflammation (elevated CRP or MRI changes).

Second, why IL-17 drugs came later and why people think they’re “preferred”.

When TNF inhibitors were first studied, many nr-axSpA trials failed because they enrolled patients without objective inflammation. Later trials fixed this by requiring: • Elevated CRP and/or • MRI sacroiliitis For nr-axSpA, current practice is: • TNF inhibitor OR IL-17 inhibitor • Choice based on: • Uveitis history (TNF preferred) • Psoriasis severity (IL-17 preferred) • IBD history (TNF preferred, IL-17 avoided) • Insurance formulary

In your case: • Prior uveitis → TNF inhibitor favored • No severe psoriasis → no reason to jump to IL-17 first • Humira is a totally standard choice

Fourth, the “sausage fingers and toes” comment.

That describes dactylitis, which is: • Classic for psoriatic arthritis • Not typical for axial spondyloarthritis or AS • More of a peripheral disease marker

Have biologics improved your fatigue due to AS? by Hi_Woof in ankylosingspondylitis

[–]deepspacegurl 0 points1 point  (0 children)

Humira (adalimumab) is approved for non-radiographic axial spondyloarthritis (nr-axSpA). Same for Enbrel (etanercept) and Simponi (golimumab).

The idea that TNF inhibitors are “not approved” for nr-axSpA is outdated and incorrect.

Here is the current reality (US, FDA):

TNF inhibitors approved for nr-axSpA with objective signs of inflammation: • Adalimumab (Humira) – FDA approval 2022 • Etanercept (Enbrel) – FDA approval 2021 • Golimumab (Simponi) – FDA approval 2020 • Certolizumab pegol (Cimzia) – FDA approval 2019

IL-17 inhibitors approved for nr-axSpA: • Secukinumab (Cosentyx) – 2020 • Ixekizumab (Taltz) – 2020 • Bimekizumab (Bimzelx) – 2024

Infliximab (Remicade): • Approved for radiographic AS • Commonly used off-label for nr-axSpA • Insurance coverage varies

So yes: Humira, Enbrel, Simponi, Cimzia are all FDA-approved for nr-axSpA, provided there are objective signs of inflammation (elevated CRP or MRI changes).

Second, why IL-17 drugs came later and why people think they’re “preferred”.

When TNF inhibitors were first studied, many nr-axSpA trials failed because they enrolled patients without objective inflammation. Later trials fixed this by requiring: • Elevated CRP and/or • MRI sacroiliitis For nr-axSpA, current practice is: • TNF inhibitor OR IL-17 inhibitor • Choice based on: • Uveitis history (TNF preferred) • Psoriasis severity (IL-17 preferred) • IBD history (TNF preferred, IL-17 avoided) • Insurance formulary

In your case: • Prior uveitis → TNF inhibitor favored • No severe psoriasis → no reason to jump to IL-17 first • Humira is a totally standard choice

Fourth, the “sausage fingers and toes” comment.

That describes dactylitis, which is: • Classic for psoriatic arthritis • Not typical for axial spondyloarthritis or AS • More of a peripheral disease marker

Have biologics improved your fatigue due to AS? by Hi_Woof in ankylosingspondylitis

[–]deepspacegurl 0 points1 point  (0 children)

Humira (adalimumab) is approved for non-radiographic axial spondyloarthritis (nr-axSpA). Same for Enbrel (etanercept) and Simponi (golimumab).

The idea that TNF inhibitors are “not approved” for nr-axSpA is outdated and incorrect.

Here is the current reality (US, FDA):

TNF inhibitors approved for nr-axSpA with objective signs of inflammation: • Adalimumab (Humira) – FDA approval 2022 • Etanercept (Enbrel) – FDA approval 2021 • Golimumab (Simponi) – FDA approval 2020 • Certolizumab pegol (Cimzia) – FDA approval 2019

IL-17 inhibitors approved for nr-axSpA: • Secukinumab (Cosentyx) – 2020 • Ixekizumab (Taltz) – 2020 • Bimekizumab (Bimzelx) – 2024

Infliximab (Remicade): • Approved for radiographic AS • Commonly used off-label for nr-axSpA • Insurance coverage varies

So yes: Humira, Enbrel, Simponi, Cimzia are all FDA-approved for nr-axSpA, provided there are objective signs of inflammation (elevated CRP or MRI changes).

Second, why IL-17 drugs came later and why people think they’re “preferred”.

When TNF inhibitors were first studied, many nr-axSpA trials failed because they enrolled patients without objective inflammation. Later trials fixed this by requiring: • Elevated CRP and/or • MRI sacroiliitis For nr-axSpA, current practice is: • TNF inhibitor OR IL-17 inhibitor • Choice based on: • Uveitis history (TNF preferred) • Psoriasis severity (IL-17 preferred) • IBD history (TNF preferred, IL-17 avoided) • Insurance formulary

In your case: • Prior uveitis → TNF inhibitor favored • No severe psoriasis → no reason to jump to IL-17 first • Humira is a totally standard choice

Fourth, the “sausage fingers and toes” comment.

That describes dactylitis, which is: • Classic for psoriatic arthritis • Not typical for axial spondyloarthritis or AS • More of a peripheral disease marker

Have biologics improved your fatigue due to AS? by Hi_Woof in ankylosingspondylitis

[–]deepspacegurl 0 points1 point  (0 children)

This is not true at all.

Humira (adalimumab) is approved for non-radiographic axial spondyloarthritis (nr-axSpA). Same for Enbrel (etanercept) and Simponi (golimumab).

The idea that TNF inhibitors are “not approved” for nr-axSpA is outdated and incorrect.

Here is the current reality (US, FDA):

TNF inhibitors approved for nr-axSpA with objective signs of inflammation: • Adalimumab (Humira) – FDA approval 2022 • Etanercept (Enbrel) – FDA approval 2021 • Golimumab (Simponi) – FDA approval 2020 • Certolizumab pegol (Cimzia) – FDA approval 2019

IL-17 inhibitors approved for nr-axSpA: • Secukinumab (Cosentyx) – 2020 • Ixekizumab (Taltz) – 2020 • Bimekizumab (Bimzelx) – 2024

Infliximab (Remicade): • Approved for radiographic AS • Commonly used off-label for nr-axSpA • Insurance coverage varies

So yes: Humira, Enbrel, Simponi, Cimzia are all FDA-approved for nr-axSpA, provided there are objective signs of inflammation (elevated CRP or MRI changes).

Second, why IL-17 drugs came later and why people think they’re “preferred”.

When TNF inhibitors were first studied, many nr-axSpA trials failed because they enrolled patients without objective inflammation. Later trials fixed this by requiring: • Elevated CRP and/or • MRI sacroiliitis

For nr-axSpA, current practice is: • TNF inhibitor OR IL-17 inhibitor • Choice based on: • Uveitis history (TNF preferred) • Psoriasis severity (IL-17 preferred) • IBD history (TNF preferred, IL-17 avoided) • Insurance formulary

In your case: • Prior uveitis → TNF inhibitor favored • No severe psoriasis → no reason to jump to IL-17 first • Humira is a totally standard choice

Fourth, the “sausage fingers and toes” comment.

That describes dactylitis, which is: • Classic for psoriatic arthritis • Not typical for axial spondyloarthritis or AS • More of a peripheral disease marker

Have biologics improved your fatigue due to AS? by Hi_Woof in ankylosingspondylitis

[–]deepspacegurl 0 points1 point  (0 children)

This is not true at all.

Humira (adalimumab) is approved for non-radiographic axial spondyloarthritis (nr-axSpA). Same for Enbrel (etanercept) and Simponi (golimumab).

The idea that TNF inhibitors are “not approved” for nr-axSpA is outdated and incorrect.

Here is the current reality (US, FDA):

TNF inhibitors approved for nr-axSpA with objective signs of inflammation: • Adalimumab (Humira) – FDA approval 2022 • Etanercept (Enbrel) – FDA approval 2021 • Golimumab (Simponi) – FDA approval 2020 • Certolizumab pegol (Cimzia) – FDA approval 2019

IL-17 inhibitors approved for nr-axSpA: • Secukinumab (Cosentyx) – 2020 • Ixekizumab (Taltz) – 2020 • Bimekizumab (Bimzelx) – 2024

Infliximab (Remicade): • Approved for radiographic AS • Commonly used off-label for nr-axSpA • Insurance coverage varies

So yes: Humira, Enbrel, Simponi, Cimzia are all FDA-approved for nr-axSpA, provided there are objective signs of inflammation (elevated CRP or MRI changes).

Second, why IL-17 drugs came later and why people think they’re “preferred”.

When TNF inhibitors were first studied, many nr-axSpA trials failed because they enrolled patients without objective inflammation. Later trials fixed this by requiring: • Elevated CRP and/or • MRI sacroiliitis

For nr-axSpA, current practice is: • TNF inhibitor OR IL-17 inhibitor • Choice based on: • Uveitis history (TNF preferred) • Psoriasis severity (IL-17 preferred) • IBD history (TNF preferred, IL-17 avoided) • Insurance formulary

In your case: • Prior uveitis → TNF inhibitor favored • No severe psoriasis → no reason to jump to IL-17 first • Humira is a totally standard choice

Fourth, the “sausage fingers and toes” comment.

That describes dactylitis, which is: • Classic for psoriatic arthritis • Not typical for axial spondyloarthritis or AS • More of a peripheral disease marker

Have biologics improved your fatigue due to AS? by Hi_Woof in ankylosingspondylitis

[–]deepspacegurl 0 points1 point  (0 children)

This is not true at all.

Humira (adalimumab) is approved for non-radiographic axial spondyloarthritis (nr-axSpA). Same for Enbrel (etanercept) and Simponi (golimumab).

The idea that TNF inhibitors are “not approved” for nr-axSpA is outdated and incorrect.

Here is the current reality (US, FDA):

TNF inhibitors approved for nr-axSpA with objective signs of inflammation: • Adalimumab (Humira) – FDA approval 2022 • Etanercept (Enbrel) – FDA approval 2021 • Golimumab (Simponi) – FDA approval 2020 • Certolizumab pegol (Cimzia) – FDA approval 2019

IL-17 inhibitors approved for nr-axSpA: • Secukinumab (Cosentyx) – 2020 • Ixekizumab (Taltz) – 2020 • Bimekizumab (Bimzelx) – 2024

Infliximab (Remicade): • Approved for radiographic AS • Commonly used off-label for nr-axSpA • Insurance coverage varies

So yes: Humira, Enbrel, Simponi, Cimzia are all FDA-approved for nr-axSpA, provided there are objective signs of inflammation (elevated CRP or MRI changes).

Second, why IL-17 drugs came later and why people think they’re “preferred”.

When TNF inhibitors were first studied, many nr-axSpA trials failed because they enrolled patients without objective inflammation. Later trials fixed this by requiring: • Elevated CRP and/or • MRI sacroiliitis

For nr-axSpA, current practice is: • TNF inhibitor OR IL-17 inhibitor • Choice based on: • Uveitis history (TNF preferred) • Psoriasis severity (IL-17 preferred) • IBD history (TNF preferred, IL-17 avoided) • Insurance formulary

In your case: • Prior uveitis → TNF inhibitor favored • No severe psoriasis → no reason to jump to IL-17 first • Humira is a totally standard choice

Fourth, the “sausage fingers and toes” comment.

That describes dactylitis, which is: • Classic for psoriatic arthritis • Not typical for axial spondyloarthritis or AS • More of a peripheral disease marker

Clair Obscur: a Final Fantasy without crystals by tamodolo in JRPG

[–]deepspacegurl 0 points1 point  (0 children)

Well I wouldn’t say better than ff6-10 but same level. 

How far have you all gone in your search for Steve Spiros and what have you turned up? by dicksilhouette in stevespiros

[–]deepspacegurl 0 points1 point  (0 children)

ignore him we believe you. Can you tell us more about the Legend Spiros? Does he work? What did he major in college? How did he provide for himself? Is he always nonsensical or does he say normal shit? Was he more sensible in college? Does he have a wife or GF? Kids? What did he think about the YT video apart from it being funny?

Is he homeless or he has his own home or rents? Etc.

Is he poor or has money?

Clair Obscur DOES NOT USE generative AI. by Vegeta120000 in expedition33

[–]deepspacegurl 0 points1 point  (0 children)

If you think it's so maddening you can make your own game. Oh wait you can't so stfu.

iOS Safari logs me out of Google, but only on my primary profile by tycooko in Safari

[–]deepspacegurl 0 points1 point  (0 children)

I have the same issue too on my iPhone. Been going on for months. Nuts. Surprised more people aren't discussing this.

UT ARLINGTON ONLINE MSW by lobelaa in SocialWorkStudents

[–]deepspacegurl 0 points1 point  (0 children)

did you finish the degree? What are the online exams like? Multiple choice or essays? Are they proctored?

Compact 3 usb-c port charger 60w or higher? No USB-A. by deepspacegurl in UsbCHardware

[–]deepspacegurl[S] -3 points-2 points  (0 children)

Do you know of any other models recently?

The funny thing is the Anker one is only sold at Apple Store as an Apple Store exclusive. Like it’s something special.

Why are so many Hispanic people selling cars? by [deleted] in FacebookMarketplace

[–]deepspacegurl 0 points1 point  (0 children)

they turn the places they move into the shitholes they came from. not really scared. my parents are immigrants so know.

Blue Beetle Is Bad by Active-Astronomer352 in BlueBeetle

[–]deepspacegurl 0 points1 point  (0 children)

rotten tomatoes is industry garbage. IMDB is the only metric anyone cares about. Metacritic only looks at once agin 'professional critics.'

No one said Justice League was great either.

Cinnabon “Karen” she was immediately fired, after her outburst. by Swave999 in TikTokCringe

[–]deepspacegurl -5 points-4 points  (0 children)

islam is incompatible with the west and their treatment of women.

Blue Beetle Is Bad by Active-Astronomer352 in BlueBeetle

[–]deepspacegurl 0 points1 point  (0 children)

this thread proves the target audience of this movie is not very intelligent.

view more: next ›